Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 7/20 | 0.73 |
| ▸ | MGLL | Q99685 | 7/20 | 0.71 |
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.54 |
| ▸ | POLB | P06746 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | LMNA | P02545 | 2/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14637350 | 0.85 | HSD11B1 (0.69) | HSD11B1MGLL | |
| SCHEMBL6140623 | 0.85 | HSD11B1 (0.66) | HSD11B1MGLLKDM2BPOLBEPHX2 | |
| SCHEMBL6235692 | 0.84 | HSD11B1 (0.67) | HSD11B1MGLLKDM2BPOLBALDH1A1 | |
| SCHEMBL12576441 | 0.84 | HSD11B1 (1.00) | HSD11B1MGLLPOLBALDH1A1LMNA | |
| SCHEMBL4236625 | 0.83 | HSD11B1 (0.65) | HSD11B1MGLLKDM2BPOLBALDH1A1 | |
| SCHEMBL14638795 | 0.81 | HSD11B1 (0.71) | HSD11B1MGLLKDM2BPOLB | |
| SCHEMBL4962237 | 0.81 | POLB (0.78) | HSD11B1MGLLPOLBALDH1A1LMNA | |
| SCHEMBL27957268 | 0.81 | HSD11B1 (0.61) | HSD11B1MGLLKDM2BPOLBALDH1A1 | |
| SCHEMBL16225106 | 0.81 | POLB (0.53) | HSD11B1MGLLPOLBALDH1A1LMNA | |
| SCHEMBL6097817 | 0.80 | EPHX2 (0.56) | HSD11B1MGLLEPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9181266-B2 | 2-piperidin-1-yl-acetamide compounds for use as tankyrase inhibitors | NOVARTIS AG (CH) | 2015-11-10 | — | — | US | disclosed |
| EP-2731942-B1 | NOVEL 2-PIPERIDIN-1-YL-ACETAMIDE COMPOUNDS FOR USE AS TANKYRASE INHIBITORS | NOVARTIS AG (CH) | 2015-09-23 | — | — | EP | disclosed |
| US-20150025070-A1 | NOVEL 2-PIPERIDIN-1-YL-ACETAMIDE COMPOUNDS FOR USE AS TANKYRASE INHIBITORS | NOVARTIS AG (CH) | 2015-01-22 | — | — | US | disclosed |
| EP-2731942-A1 | NOVEL 2-PIPERIDIN-1-YL-ACETAMIDE COMPOUNDS FOR USE AS TANKYRASE INHIBITORS | Novartis AG (CH) | 2014-05-21 | — | — | EP | disclosed |
| CN-103781776-A | Novel 2-piperidin-1-yl-acetamide compounds for use as tankyrase inhibitors | NOVARTIS AG | 2014-05-07 | — | — | CN | disclosed |
| WO-2013012723-A1 | NOVEL 2-PIPERIDIN-1-YL-ACETAMIDE COMPOUNDS FOR USE AS TANKYRASE INHIBITORS | NOVARTIS AG (CH) | 2013-01-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150025070-A1 | NOVEL 2-PIPERIDIN-1-YL-ACETAMIDE COMPOUNDS FOR USE AS TANKYRASE INHIBITORS | WNT1, TNKS1BP1, TNKS | HSD11B1 2796/4885MGLL 2699/4885KDM2B 1161/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.